Type of provider important among CME program users

Share this article:
A new survey suggests that CME programs created by medical communications agencies achieve a higher level of acceptance among physicians when the agencies partner with university medical schools to accredit the educational offerings.
CME provider Rogers Medical Intelligence Solutions surveyed 2000 U.S. physicians to gather data on their CME preferences.
The survey results found that the type of provider is an important factor for 60 percent of physicians when they choose to participate in a given CME program.
Universities (medical schools) stood out as the most preferred accreditors, getting the nod of 91 percent of survey respondents.
Universities were trailed by medical societies at 57 percent, while hospitals and programs self-accredited by medical communications agencies are virtually tied for a more distant third (22 percent and 20 percent of physicians, respectively, expressed a preference for these types of CME providers).
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...